The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency

Generalized Arterial Calcification of Infancy Clinical Trial

Official title:

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children With Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06046820
• Other study ID #: INZ701-106
• Status: Recruiting
• Phase: Phase 3
• Start date: November 5, 2023
• Est. completion date: June 2025

Study information

• Verified date: April 2024
• Source: Inozyme Pharma
• Contact: Inozyme Clinical Trial Information
• Phone: +1 857 330 4340
• Email: clinicaltrials[@]inozyme.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.

Description:

INZ-701 is an ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzyme replacement therapy (ERT) in development for the treatment of ENPP1 Deficiency, an ultra-rare genetic disorder with an incidence of 1 in 64,000 pregnancies. Study INZ701-106 (The ENERGY 3 Study) is a multi-center, randomized in a 2:1 ratio, controlled, open-label Phase 3 study to evaluate the efficacy and safety of INZ-701 in children with ENPP1 Deficiency. The study will consist of a Screening Period of up to 52 days (including a washout period of up to 7 days for prohibited medications post-Randomization) and a Randomized Treatment Period (INZ-701 or control) of 52 weeks, followed by an Open-label Extension Period during which all study participants may receive INZ-701, and an End of Study (EOS) Safety visit 30 days after the last dose of INZ-701.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: June 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 12 Years

Eligibility

Inclusion Criteria

Study participants must meet all of the following inclusion criteria:

1. Caregiver's written or electronic informed consent after the nature of the study has been explained, and prior to any research-related procedures, per International Conference on Harmonisation (ICH) Good Clinical Practice (GCP)

2. Study participant's assent in accordance with local regulations

3. A confirmed postnatal molecular genetic diagnosis of ENPP1 Deficiency with biallelic mutations (ie, homozygous or compound heterozygous) performed by a College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) certified laboratory or regional equivalent

4. Males and females =1 year and <13 years of age at Study Day 1

5. Open growth plates of the distal femur and proximal tibia in both legs

6. Plasma PPi concentration of <1400 nM at Screening

7. 25-hydroxyvitamin D (25[OH]D) levels of =12 ng/mL at Screening

8. Radiographic evidence of skeletal abnormalities based on an RSS =2

9. Female participants of childbearing potential must have a negative serum pregnancy test at Screening and must not be breastfeeding

10. Study participants of childbearing potential who are sexually active must agree to use a highly effective form of contraception in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) guidance and local guidelines for the duration of the study

11. In the opinion of the Investigator, able to complete all aspects of the study Exclusion Criteria Study participants meeting any of the following exclusion criteria will not be eligible to

participate in the study:

1. In the opinion of the Investigator, has clinically significant disease or laboratory abnormality not associated with ENPP1 Deficiency that will preclude study participation and/or may confound the interpretation of study results

2. If receiving any of the following prohibited medications as indicated in the protocol:

systemic corticosteroids (>5 mg prednisone equivalent per day), anti-fibroblast growth factor 23 (FGF23), and oral and/or IV bisphosphonates

3. Unable or unwilling to discontinue calcitriol or other active forms of vitamin D3 (or analogs) within 7 days prior to Study Day 1 and/or oral phosphate supplements within 36 hours prior to Study Day 1 if randomized to the INZ-701 arm

4. Planned orthopedic surgery that may confound the interpretation of study results during the 52-week Randomized Treatment Period

5. Known intolerance to INZ-701 or any of its excipients

6. A positive COVID-19 test within 5 days prior to Randomization, only if required as per local regulations or institutional policy

7. Previous treatment with INZ-701

8. Concurrent participation in another interventional clinical study and/or has received an investigational drug within 5 half-lives of the last dose or within 4 weeks prior to Randomization, whichever is longer, or use of an investigational device

Related Conditions & MeSH terms

• Autosomal Recessive Hypophosphatemic Rickets
• Calcinosis
• Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency
• Familial Hypophosphatemic Rickets
• Generalized Arterial Calcification of Infancy
• Rickets
• Vascular Calcification

Intervention

Drug:
• INZ-701
Recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody.
• Control Arm (Conventional Therapy)
Conventional therapy is defined as oral phosphate supplements and calcitriol or other active forms of vitamin D3 (or analogs). No other agents for treatment of ENPP1 Deficiency are allowed in the control arm.

Locations

Country	Name	City	State
Canada	Centre Hospitalier Universitaire (CHU) Sainte-Justine	Montréal
United Kingdom	Royal Manchester Children's Hospital	Manchester
United States	Ann & Robert H. Lurie Children's Hospital	Chicago	Illinois
United States	Cook Children's Medical Center	Fort Worth	Texas
United States	The Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Inozyme Pharma

Countries where clinical trial is conducted

United States,  Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) concentration through Week 52	For each subject, plasma PPi will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	52 weeks (Baseline through Week 52)
Secondary	Change from Baseline in skeletal abnormalities as measured by the Radiographic Global Impression of Change (RGI-C) global score through Week 52	The RGI-C is an overall radiographic score which can be used to monitor response to a therapeutic intervention comparing scores from 2 time points. A determination of healing on a scale of 0 to +3 with 0 being no change or healing and +3 being complete healing; worsening is also measured on a scale of 0 to -3 with 0 being no change and -3 being severe worsening.	Baseline, Week 26, Week 52
Secondary	Change from Baseline in rickets as measured by Rickets Severity Score (RSS) total score through Week 52	The RSS assesses rickets severity by utilizing a scoring system that uses a scale from 0 to 4 for the wrists and 0 to 6 for the knees, to generate a total score of 0 to 10, where 0 is normal and 10 is the worst score possible ie, most severe skeletal abnormalities observed radiographically.	Baseline, Week 26, Week 52
Secondary	Change from Baseline in growth Z-score (height/body length and weight) through Week 52	A Z-score represents the degree to which that particular measurement for that individual differs from the reference value in the general population.; (height/body length and weight) through Week 52	Baseline, Day 29, Week 8, Week 13, Week 26, Week 39, Week 52
Secondary	Area under the Plasma Concentration versus Time Curve (AUC) of INZ-701	For each subject, variation of concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	52 weeks (Randomized Treatment Period)
Secondary	Maximum Plasma Concentration (Cmax) of INZ-701	For each subject, the maximum concentration of INZ-701 in the plasma will be measured via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	52 weeks (Randomized Treatment Period)
Secondary	Change from Baseline in ENPP1 activity (µM/min) through week 52	For each subject, the activity of INZ-701 (µM/min) in the serum will be assessed through hydrolysis of a substrate to the enzyme, via a series of blood samples obtained throughout the study, comparing the subject's baseline value over time.	52 weeks (Randomized Treatment Period)